Virtus Biotech ETF (BBP)
Market Closed
26 Oct, 08:00 PM
ARCA ARCA Primary 
SGX $
101. 98
-0.09
-0.0882%
$
41.59M Market Cap
0.29% Div Yield
92 Volume
$ 102.07
Previous Close Investors:
Want to track BBP and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
BBP: The Biotech ETF That Filters For FDA-Approved Drugs
Virtus Biotech ETF (BBP) is rated a buy for its focused exposure to FDA-approved biotech firms and strong recent outperformance. BBP's equal-weight, quarterly rebalancing strategy efficiently captures upside from breakout holdings like MRNA while reducing speculative risk. Rising sector deal activity and GLP-1 market expansion underpin a favorable outlook for BBP despite macro headwinds like higher interest rates.
Seekingalpha | 2 months ago
2026 © Marketlog. All Rights Reserved.
